Abstract: A data ingestion system normalizes ingested documents and extracts data based on a template that is applied to the documents. In an aspect, the system accesses a document of a document type and determines a template to apply to the document. The system normalizes the document, extracts data values from the document based at least in part on the template, and generates structured data based at least partly on the extracted data.

Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1? binding molecules such as an anti-IL-1? antibody or binding fragment thereof.

Abstract: Methods and compositions are disclosed utilizing optically pure (?) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (?) isomer is also useful for the treatment of gastroesophageal reflux. (?) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract: Stable pharmaceutical compositions of descarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include lactose-free, non-hygroscopic and anhydrous stable pharmaceutical compositions of DCL.

Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone.

Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.

Abstract: An information management and synchronous communications system and method facilitates database equilibrium and synchronization with wired, wireless and Web-based systems, user-friendly and efficient generation of computerized menus and reservations with handwritten/voice modifications for restaurants and other applications that utilize equipment with nonstandard graphical formats, display sizes and/or applications for use in remote data entry, information management and communication with host computer, digital input device or, remote pager via standard hardwired connection, the internet, a wireless link, printer or the like.

Abstract: Methods and compositions are disclosed utilizing optically pure S(?)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(?) isomer is also useful for the treatment of gastroesophageal reflux. S(?)rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (?) stereoisomer.

Abstract: Ototoxic side-effects have either limited the application of an important group of antibiotics, aminoglycoside antibiotics, or have added further burden to those who have to resort to platinum-containing antineoplastic agents to treat life-threatening tumors. The present invention discloses pharmaceutical compositions that prevent or treat the ototoxic side-effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents. The otoprotective compositions disclosed herein can also be used to treat noise induced hearing loss.

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (?) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract: The present invention provides methods and compositions for conjoint administration of a nefazodonoid and a fluoxetinoid for the treatment of depression and other neurological conditions.

Abstract: The present invention relates to compounds capable of inhibiting leukotriene activity and histamine activity, and their use in treating asthma and allergic conditions such as hay fever, dermatitus, and urticaria. Inhibition of both pathways permits more effective treatment of conditions with fewer side effects than can be achieved using most available antihistamines alone.

Abstract: A trusted agent server provides a networked application that assists a customer in managing their online commercial affairs. A user contacts the server using a network access device, such as a browser on a personal computer. The trusted agent client component augments the user's network access device to perform business transactions on behalf of the user. The user controls these transactions through the trusted agent server. A trusted agent service is a trusted agent client component application which operates in conjunction with the trusted agent server. The trusted agent service is an Internet-based mechanism that makes single-click buying available on any commercial Web site. The trusted agent also provides customers with access to personal and credit card information used during single-click transactions, smart receipts used for ongoing customer support, merchant and product preference settings, and direct response product offerings keyed to these preferences.